Brain-computer interfaces (BCIs) have transitioned from theoretical research to working medical devices in human patients, with multiple competing approaches now producing measurable results for people with severe paralysis. In 2024, Neuralink implanted its first device in a human patient, and by early 2026, the competitive landscape has expanded far beyond Elon Musk's company, with Synchron, BrainGate, and other organizations demonstrating that different technological approaches can successfully translate brain signals into computer commands.

What Brain-Computer Interfaces Can Actually Do Right Now?

Current BCI technology enables paralyzed patients to control a computer cursor, type text, browse the internet, play games, and operate assistive technology using thought alone. The best systems achieve cursor control speeds roughly equivalent to using a trackpad, which is functional for computer use but significantly slower than able-bodied hand control. Speech BCIs represent perhaps the most transformative application, translating attempted speech into text at rates approaching 60 words per minute, approaching natural conversation speed. Robotic arm control through BCIs has been demonstrated in research settings, allowing paralyzed patients to grasp objects, bring food to their mouth, and perform basic manipulation tasks, though these demonstrations remain limited to controlled laboratory environments with specialized robotic hardware.

What BCIs cannot do is equally important to understand. Current systems cannot restore natural sensation, enable thought-to-thought communication between people, enhance cognitive abilities in healthy individuals, or read complex thoughts, emotions, or memories. These capabilities range from distant future research goals to fundamental misunderstandings of what neural interfaces actually measure.

How Do Different Brain-Computer Interface Approaches Compare?

• Neuralink's Invasive Approach: Uses a robotic surgeon to insert 1,024 ultra-thin electrode threads directly into the motor cortex, reading electrical signals when patients think about movement. The first patient, Noland Arbaugh, achieved cursor control speeds competitive with systems developed over decades, and wireless transmission eliminated infection-prone external connectors. However, several electrode threads retracted from optimal positions weeks after implantation, reducing signal quality, though subsequent implants have improved thread retention through modified surgical techniques.
• Synchron's Less Invasive Alternative: Implants a small mesh stent called a Stentrode through the jugular vein, navigating it to the motor cortex where it reads neural signals through the blood vessel wall, resembling a routine cardiac stent procedure. This approach avoids open brain surgery, eliminating risks of tissue damage and infection, with recovery measured in days rather than weeks. The trade-off is lower signal resolution; Stentrode patients achieve slower cursor control speeds than Neuralink patients, though long-term data shows devices remaining functional and stable for over two years without migration or signal degradation.
• BrainGate's Academic Pioneer Model: Developed through collaboration between Brown University, Stanford, and Massachusetts General Hospital since 2004, using a Utah Array electrode that sits on the motor cortex surface. Their longest-running patient has used a BCI for over a decade, providing the most extensive longitudinal data showing that signal quality degrades gradually as scar tissue forms, but useful function persists for years. Recent research has expanded to speech decoding, translating paralyzed patients' attempted speech into text at rates approaching 60 words per minute.

Each approach represents a different point on the spectrum between invasiveness and signal quality. Neuralink's direct electrode insertion provides the highest-fidelity signals but carries greater surgical risk. Synchron's vascular approach minimizes surgical risk but produces lower-resolution data that requires more sophisticated signal processing to achieve functional results. BrainGate's surface electrodes occupy a middle ground, with the longest track record of long-term stability in human patients.

When Will Brain-Computer Interfaces Become Available to Patients?

No BCI is commercially available in 2026. All current implants are performed under research protocols or expanded access programs. Neuralink and Synchron are both pursuing FDA (Food and Drug Administration) pathways that could lead to commercial approval, but realistic timelines extend to 2028-2030 for limited commercial availability. When BCIs become commercially available, the initial patient population will be limited to people with severe paralysis who have no alternative means of computer access or communication.

The cost of BCI implantation is currently covered by research funding. Commercial pricing is unknown but expected to be in the range of tens of thousands of dollars for the device plus surgical implantation costs. Insurance coverage will depend on regulatory classification and clinical evidence of benefit. Expansion to broader populations, including treatment of conditions like depression, epilepsy, and chronic pain through neural modulation, represents a subsequent phase of development that remains years away.

What Ethical Questions Does Brain-Computer Interface Technology Raise?

BCI development raises questions that the technology's current limitations make theoretical but not irrelevant. Data privacy for neural signals represents a fundamental concern; as BCIs become more sophisticated, the question of who owns and controls brain data becomes increasingly important. Consent protocols for patients with severe communication impairments require careful design, since the very condition that makes BCI implantation beneficial may limit a patient's ability to fully understand and consent to the procedure.

Equitable access to expensive implanted technology poses another challenge. If BCI implantation costs tens of thousands of dollars, access will initially be limited to wealthy patients or those with comprehensive insurance coverage, potentially creating a two-tiered system where only some paralyzed patients can benefit from the technology. The long-term implications of commercial companies having access to brain data also require careful governance frameworks, as neural signals may eventually reveal information about cognitive function, emotional states, or neurological conditions that patients may not wish to disclose.

The immediate ethical landscape is relatively straightforward: the technology helps severely disabled people regain function, and the risks are disclosed through informed consent processes. However, as BCI technology becomes more capable and more widely deployed, these governance questions will move from theoretical to urgent.